May 26, 2023 11:04 AM EDTUpdated May 30, 07:22 AM

Corrected: BenchSci raises $70M Series D for drug discovery software; Zentalis touts PhIb ovarian cancer data

Amber Tong

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Canada’s BenchSci has raised $70 million in a Series D round designed to scale its AI drug discovery platform for scientists working in preclinical research …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corrected: BenchSci raises $70M Series D for drug discovery software; Zentalis touts PhIb ovarian cancer data

Amber Tong

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Cor­rect­ed: Bench­Sci rais­es $70M Se­ries D for drug dis­cov­ery soft­ware; Zen­tal­is touts PhIb ovar­i­an can­cer da­ta

Senior Editor

Senior Reporter

Sign up to read this article for free.

Corrected: BenchSci raises $70M Series D for drug discovery software; Zentalis touts PhIb ovarian cancer data